GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » PB Ratio

Aerie Pharmaceuticals (Aerie Pharmaceuticals) PB Ratio : (As of May. 04, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-04), Aerie Pharmaceuticals's share price is $15.25. Aerie Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2022 was $-3.32. Hence, Aerie Pharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for Aerie Pharmaceuticals's PB Ratio or its related term are showing as below:

During the past 11 years, Aerie Pharmaceuticals's highest PB Ratio was 35.92. The lowest was 0.00. And the median was 8.08.

AERI's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.97
* Ranked among companies with meaningful PB Ratio only.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Aerie Pharmaceuticals was 91.80% per year. The lowest was -48.10% per year. And the median was 4.50% per year.

Back to Basics: PB Ratio


Aerie Pharmaceuticals PB Ratio Historical Data

The historical data trend for Aerie Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals PB Ratio Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.28 7.21 6.73 26.39 -

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aerie Pharmaceuticals's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's PB Ratio falls into.



Aerie Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Aerie Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2022)
=15.25/-3.32
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Aerie Pharmaceuticals  (NAS:AERI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Aerie Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Headlines